查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493374

自体免疫溶血性贫血治疗市场规模、份额和趋势分析报告：按类型、药物类别、给药途径、分销管道、地区和细分市场趋势：2024-2030

Autoimmune Hemolytic Anemia Treatment Market Size, Share & Trends Analysis Report By Type, By Drug Class (Corticosteroids, Immunosuppressive Agents), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

自体免疫溶血性贫血治疗市场的成长与趋势：

Grand View Research, Inc.最新报告显示，2030年全球自体免疫溶血性贫血治疗市场预计将达到11.6亿美元，2024年至2030年复合年增长率为6.5%。

全球自体免疫免疫性溶血性贫血 (AIHA) 病例数量不断增加、新治疗药物的推出、研发活动的活性化以及积极主动的政府倡议是推动增长的关键因素。例如，法国和丹麦的 AIHA 发生率估计分别为每 10 万人 2.4 例和 17.0 例。

治疗 AIHA开发新药的研发势头强劲，预计将成为市场扩张的驱动力。製药公司和研究机构正在积极致力于开发新的有效治疗方法来管理 AIHA。例如，Zenas BioPharma 正在开发用于温性自体免疫溶血性贫血 (wAIHA) 患者的 obexelimab。该药物正在进行 3 期临床试验，评估其对 wAIHA 患者的疗效和安全性。同样，诺华正在进行一项临床试验，以评估 ianalumab (VAY736) 对于至少一种热自体免疫溶血性贫血治疗失败的患者的安全性和有效性。

此外，由于政府机构的更多参与以及监管机构为改善罕见疾病管理的医疗服务而采取的有利倡议，预计未来几年将推出有效的治疗解决方案。例如，2019年12月，美国FDA授予nipocalimab治疗wAIHA的孤儿药资格，2019年7月，美国FDA授予nipocalimab用于同一适应症的简审类。候选化合物的这一特殊指定预计将加快临床试验和核准过程。

主要参与者正在采取各种市场策略，例如收购和新产品开发，以巩固其市场地位。例如，2023年9月，百时美施贵宝以5,000万美元从Zenas Biopharma收购双功能单株抗体obexelimab的亚洲行销权。此外，2022年6月，Rigel Pharmaceuticals公布了fostamatinib在wAIHA患者中的3期临床试验结果，研究地点位于美国、加拿大、澳洲和西欧，结果显示接受fostamatinib治疗的患者。 。

自体免疫溶血性贫血治疗市场报告亮点

  • 由于wAIHA的高盛行率和高治疗率，2023年自体免疫免疫性溶血性贫血治疗市场以温性自体免疫溶血性贫血为主。
  • 由于处方率高，皮质类固醇在 2023 年占据最大的市场占有率。此外，皮质类固醇被认为是治疗AIHA的第一线药物。
  • 由于生物製药研发和核准的增加，预计其他药物类别在未来几年将经历最快的成长。
  • 从给药途径来看，由于越来越多地采用以患者为中心的方法以及正在研发中的有前途的口服药物（例如利扎布替尼），口服药物预计将增长最快。
  • 由于疾病盛行率高、市场参与者强大以及该地区良好的报销政策等因素，北美在市场上占据主导地位。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章自体免疫溶血性贫血治疗市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 自体免疫溶血性贫血治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章自体免疫溶血性贫血治疗市场：类型估计与趋势分析

  • 全球自体免疫溶血性贫血治疗市场：类型仪表板
  • 全球自体免疫溶血性贫血治疗市场：类型变异分析
  • 全球自体免疫溶血性贫血治疗市场：按类型分類的收益
  • 温性自体免疫溶血性贫血
  • 寒冷性自体免疫溶血性贫血
  • 其他的

第五章自体免疫溶血性贫血治疗市场：药物类别估计与趋势分析

  • 全球自体免疫溶血性贫血治疗市场：药物类别仪表板
  • 全球自体免疫免疫溶血性贫血治疗市场：药物类别变异分析
  • 全球自体免疫溶血性贫血治疗市场：按药物类别分類的收益
  • 皮质类固醇
  • 免疫抑制剂
  • 其他的

第六章自体免疫溶血性贫血治疗市场：给药途径预估及趋势分析

  • 全球自体免疫溶血性贫血治疗市场：途径仪表板
  • 全球自体免疫溶血性贫血治疗市场：给药途径变化分析
  • 全球自体免疫溶血性贫血治疗市场依给药途径及收益
  • 可注射的
  • 口服
  • 其他的

第七章自体免疫溶血性贫血治疗市场：通路估计与趋势分析

  • 全球自体免疫溶血性贫血治疗市场：通路仪表板
  • 全球自体免疫溶血性贫血治疗市场：通路波动分析
  • 全球自体免疫溶血性贫血治疗市场：按通路收益
  • 医院药房
  • 零售药房
  • 网路药房

第八章自体免疫溶血性贫血治疗市场：按类型、药物类别、给药途径和分销管道分類的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • F. Hoffmann-La Roche Ltd
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Lupin
    • Johnson &Johnson Services, Inc.
    • Novartis AG
    • Incyte
    • Rigel Pharmaceuticals, Inc.
    • Alpine Immune Sciences.
Product Code: GVR-4-68040-290-0

Autoimmune Hemolytic Anemia Treatment Market Growth & Trends:

The global autoimmune hemolytic anemia treatment market is anticipated to reach USD 1.16 billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing number of autoimmune hemolytic anemia (AIHA) cases worldwide, introduction of novel therapeutic drugs, increasing R&D activities, and favorable government initiatives are some of key factors driving the growth. For instance, the incidence of AIHA in France and Denmark is estimated at around 2.4 per 100,000 and 17.0 per 100,000 population, respectively.

Increasing research & activities to develop novel drugs for AIHA treatment is anticipated to drive the market expansion. Pharmaceutical companies and research institutes are actively involved in the development of novel and effective treatment options to manage AIHA. For instance, Zenas BioPharma is involved in the development of obexelimab for patients with warm autoimmune hemolytic anemia(wAIHA). The drug is in phase 3 of clinical trials and is being evaluated for efficacy and safety in patients with wAIHA. Similarly, Novartis AG is conducting clinical trials to evaluate the safety and efficacy of Ianalumab (VAY736) in patients who failed at least one line of treatment for warm autoimmune hemolytic anemia.

Moreover, the increasing involvement of government institutes and favorable initiatives undertaken by regulatory bodies to improve healthcare services to manage rare diseases are expected to increase the introduction of effective therapeutic solutions in the coming years. For instance, in December 2019, the U.S. FDA granted orphan drug designation to nipocalimab for the treatment of wAIHA and in July 2019, the U.S. FDA granted fast track designation for nipocalimab for the same indication. Such special designations for investigating candidates are expected to speed up the clinical trials and approval process.

Key players are adopting various market strategies such as acquisition and new product development to strengthen their market position. For instance, in September 2023, Bristol Myers Squibb acquired Asian regional market rights for bifunctional monoclonal antibody obexelimab from Zenas BioPharma, paying USD 50 million. Moreover, in June 2022, Rigel Pharmaceuticals, Inc. announced the results of phase 3 clinical trials of fostamatinib in patients with wAIHA, showing that patients treated with fostamatinib had a favorable durable hemoglobin response at the U.S., Canadian, Australian, and Western European trial sites.

Autoimmune Hemolytic Anemia Treatment Market Report Highlights:

  • The warm autoimmune hemolytic anemia type segment dominated the market in 2023 owing to a high prevalence of wAIHA and treatment rate.
  • The corticosteroids segment held the largest market share in 2023, owing to the high prescription rate. Moreover, corticosteroids are considered as the first line of treatment for AIHA.
  • The other drug class segment is projected to experience the fastest growth during the projected years owing to increasing R&D and approval of biological drugs.
  • In the route of administration segment, oral drugs are anticipated to grow at the fastest rate owing to the increasing adoption of patient-centric approaches and the presence of promising oral drugs such as rilzabrutinib in the pipeline.
  • North America dominated the market owing to factors such as high disease incidence, the presence of strong market players, and better reimbursement policies in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug Class
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type and drug class outlook
    • 2.2.2. Route of administration and distribution channel outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Autoimmune Hemolytic Anemia Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing incidence of disease
      • 3.2.1.2. Increasing geriatric population
      • 3.2.1.3. Rise in R&D activities
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of novel drug development for rare diseases
  • 3.3. Autoimmune Hemolytic Anemia Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Autoimmune Hemolytic Anemia Treatment Market: Type Estimates & Trend Analysis

  • 4.1. Global Autoimmune Hemolytic Anemia Treatment Market: Type Dashboard
  • 4.2. Global Autoimmune Hemolytic Anemia Treatment Market: Type Movement Analysis
  • 4.3. Global Autoimmune Hemolytic Anemia Treatment Market by Type, Revenue
  • 4.4. Warm Autoimmune Hemolytic Anemia
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Cold Autoimmune Hemolytic Anemia
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Autoimmune Hemolytic Anemia Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. Global Autoimmune Hemolytic Anemia Treatment Market: Drug Class Dashboard
  • 5.2. Global Autoimmune Hemolytic Anemia Treatment Market: Drug Class Movement Analysis
  • 5.3. Global Autoimmune Hemolytic Anemia Treatment Market by Drug Class, Revenue
  • 5.4. Corticosteroids
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Immunosuppressive agents
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Autoimmune Hemolytic Anemia Treatment Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Global Autoimmune Hemolytic Anemia Treatment Market: Route of Administration Dashboard
  • 6.2. Global Autoimmune Hemolytic Anemia Treatment Market: Route of Administration Movement Analysis
  • 6.3. Global Autoimmune Hemolytic Anemia Treatment Market by Route of Administration, Revenue
  • 6.4. Injectable
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Oral
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Autoimmune Hemolytic Anemia Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Global Autoimmune Hemolytic Anemia Treatment Market: Distribution Channel Dashboard
  • 7.2. Global Autoimmune Hemolytic Anemia Treatment Market: Distribution Channel Movement Analysis
  • 7.3. Global Autoimmune Hemolytic Anemia Treatment Market by Distribution Channel, Revenue
  • 7.4. Hospital Pharmacy
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Retail Pharmacy
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Online Pharmacy
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Autoimmune Hemolytic Anemia Treatment Market: Regional Estimates & Trend Analysis by Type, Drug Class, Route of Administration, and Distribution Channel

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Mexico
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Argentina
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. F. Hoffmann-La Roche Ltd
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Viatris Inc.
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Teva Pharmaceutical Industries Ltd.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Sanofi
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Lupin
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Johnson & Johnson Services, Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Novartis AG
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Incyte
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Rigel Pharmaceuticals, Inc.
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Alpine Immune Sciences.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America autoimmune hemolytic anemia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 3 North America autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 North America autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 North America autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 U.S. autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 U.S. autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 U.S. autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Canada autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 12 Canada autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Canada autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 Canada autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe autoimmune hemolytic anemia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 17 Europe autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Europe autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Europe autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Germany autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 21 Germany autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Germany autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Germany autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 UK autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 25 UK autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 UK autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 UK autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 France autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 29 France autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 France autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 France autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 Italy autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 33 Italy autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Italy autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 Italy autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 37 Spain autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Spain autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Spain autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Denmark autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 41 Denmark autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Denmark autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Denmark autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Sweden autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 45 Sweden autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 Sweden autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Sweden autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Norway autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 49 Norway autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Norway autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Norway autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific autoimmune hemolytic anemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 Aisa Pacific autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Aisa Pacific autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 China autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 58 China autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 China autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 China autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Japan autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 62 Japan autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 63 Japan autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Japan autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 India autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 66 India autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 67 India autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 68 India autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 South Korea autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 70 South Korea autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 71 South Korea autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 South Korea autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 73 Australia autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 74 Australia autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 75 Australia autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Australia autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Thailand autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 78 Thailand autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 79 Thailand autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 Thailand autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 81 Latin America autoimmune hemolytic anemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 82 Latin America autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 83 Latin America autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 84 Latin America autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 Latin America autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Brazil autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 87 Brazil autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 88 Brazil autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Brazil autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 Mexico autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 91 Mexico autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 92 Mexico autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 93 Mexico autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 94 Argentina autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 95 Argentina autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 96 Argentina autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 97 Argentina autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 98 MEA autoimmune hemolytic anemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 99 MEA autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 100 MEA autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 101 MEA autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 102 MEA autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 South Africa autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 104 South Africa autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 105 South Africa autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 106 South Africa autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 111 UAE autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 112 UAE autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 113 UAE autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 114 UAE autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 115 Kuwait autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 116 Kuwait autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 117 Kuwait autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 118 Kuwait autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Autoimmune hemolytic anemia treatment market: market outlook
  • Fig. 14 Autoimmune hemolytic anemia treatment competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Autoimmune hemolytic anemia treatment market driver impact
  • Fig. 18 Autoimmune hemolytic anemia treatment market restraint impact
  • Fig. 19 Autoimmune hemolytic anemia treatment market: Type movement analysis
  • Fig. 20 Autoimmune hemolytic anemia treatment market: Type outlook and key takeaways
  • Fig. 21 Warm autoimmune hemolytic anemia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Cold autoimmune hemolytic anemia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Autoimmune hemolytic anemia treatment market: Drug class movement analysis
  • Fig. 25 Autoimmune hemolytic anemia treatment market: Drug class outlook and key takeaways
  • Fig. 26 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Immunosuppressive agents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Autoimmune hemolytic anemia treatment market: Route of administration movement analysis
  • Fig. 30 Autoimmune hemolytic anemia treatment market: Route of administration outlook and key takeaways
  • Fig. 31 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Autoimmune hemolytic anemia treatment market: Distribution channel movement analysis
  • Fig. 35 Autoimmune hemolytic anemia treatment market: Distribution channel outlook and key takeaways
  • Fig. 36 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Global Autoimmune hemolytic anemia treatment market: Regional movement analysis
  • Fig. 40 Global Autoimmune hemolytic anemia treatment market: Regional outlook and key takeaways
  • Fig. 41 Global Autoimmune hemolytic anemia treatment market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. key country dynamics
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Canada key country dynamics
  • Fig. 47 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UK key country dynamics
  • Fig. 50 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Germany key country dynamics
  • Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 France key country dynamics
  • Fig. 54 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Italy key country dynamics
  • Fig. 56 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Spain key country dynamics
  • Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Denmark key country dynamics
  • Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Sweden key country dynamics
  • Fig. 62 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Norway key country dynamics
  • Fig. 64 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 China key country dynamics
  • Fig. 67 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Japan key country dynamics
  • Fig. 69 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 India key country dynamics
  • Fig. 71 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand key country dynamics
  • Fig. 73 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 South Korea key country dynamics
  • Fig. 75 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Australia key country dynamics
  • Fig. 77 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Brazil key country dynamics
  • Fig. 80 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Mexico key country dynamics
  • Fig. 82 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Argentina key country dynamics
  • Fig. 84 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 South Africa key country dynamics
  • Fig. 87 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia key country dynamics
  • Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 UAE key country dynamics
  • Fig. 91 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait key country dynamics
  • Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Market share of key market players- 2023